Lazard Capital Starts Endologix (ELGX) at Buy
ELGX Hot Sheet
Rating Summary:5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Lazard Capital initiates coverage on Endologix (Nasdaq: ELGX) with a Buy rating and $6 price target.
Endologix, Inc. engages in the development, manufacture, marketing, and sale of minimally invasive therapies for the treatment of vascular diseases.
Endologix, Inc. engages in the development, manufacture, marketing, and sale of minimally invasive therapies for the treatment of vascular diseases.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Wunderlich Securities Starts Anixter International (AXE) at Buy
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
New CoverageRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
